Stryker still shows strong financial health through durable growth, cash generation, and disciplined leverage, but Q1 2026 introduced near-term pressure FY2025 Adjusted Operating Income Margin was 2630%, while Q1 2026 Adjusted Operating Margin reset to 2110% after operational disruption and tariff headwinds Liquidity remained supported by Cash And Cash Equivalents of $288B at 2026-03-31 and a target gross debt/EBITDA ratio of approximately 21x Investors should treat returns as supported by reinvestment, M&A, and dividends, but monitor cash conversion and margin recovery
Financial Health Snapshot
What Does Stryker Corporation’s Latest Financial Snapshot Show?
Stryker Corporation looks Strong, with full-year sales and operating cash generation standing out most. The main concern is weaker latest cash conversion and pressure in the 2026-03-31 period.
For the latest verified fiscal periods, this view blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. For background on the business model, see Stryker Corporation (SYK): History, Ownership, Mission, How It Works & Makes Money.
Free cash flow deserves deeper analysis first, because the latest negative growth signal can change how investors read Stryker Corporation’s operating strength and capital flexibility.
Revenue and Earnings Quality
How durable are Stryker Corporation’s revenue and earnings?
Mixed. Stryker Corporation’s reported sales growth is solid, but the clearest divergence is weaker per-share conversion, with Q1 2026 Adjusted EPS Growth at -845% and a separate 2026-03-31 Revenue Growth figure of -1605% that must be kept distinct from reported Q1 growth.
Stryker Corporation is growing in quantity, but quality is more uneven. Investors compare revenue durability with operating income, net income, and EPS across the same annual or quarterly periods to see whether sales growth turns into profit growth, or whether mix, costs, acquisition effects, or timing pressure the bottom line. For deeper academic work, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help organize that split between growth and earnings quality. You can also review Exploring Stryker Corporation (SYK) Investor Profile: Who's Buying and Why? for ownership context.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $602B, 263%, Q1 2026 reported net sales | Comparable prior-period figure not supplied | Reported growth; underlying split between organic, acquired, price-led, or volume-led is unclear | The top line is expanding, but investors still need the growth source to judge repeatability |
| Operating Income | $93600M, Q1 2026 | Comparable prior-period figure not supplied | Direction versus revenue cannot be confirmed from the supplied prior period | Operating leverage is harder to judge without the matching earlier quarter |
| Net Income | $74500M, Q1 2026 | Comparable prior-period figure not supplied | Operating, interest, tax, and unusual-item effects are not fully supplied | Final earnings are positive, but the bridge from sales to net income is not fully visible |
| Diluted EPS | $193, Q1 2026 | Comparable prior-period figure not supplied | Share-count impact cannot be isolated from the supplied data | Per-share growth is harder to confirm than reported sales growth |
How durable is Stryker Corporation’s revenue?
Durability looks fairly strong because Stryker Corporation benefits from procedure-and-installed-base demand, recurring consumables, and service revenue, but visibility is still limited by hospital and ambulatory surgery center procedure volume and product concentration.
- Demand Quality: Procedure-linked demand and installed-base service revenue support recurrence, but hospital and ambulatory surgery center volumes still matter.
- Pricing and Volume: The supplied data do not cleanly separate price, volume, and mix, so the mix of drivers is not fully verified.
- Diversification: MedSurg and Neurotechnology sales of $1565B were 62% of total company revenue, and Orthopaedics sales of $947B were 38%; Mako also supports visibility, with over two-thirds of US knee procedures and one-third of US hip procedures performed on the platform.
That mix should be read alongside profitability and cash conversion, especially as the January 06, 2025 agreement to acquire Inari Medical, Inc and the May 07, 2026 completed AVS acquisition for approximately $835M add portfolio and integration risk.
Margins and cash quality
Are Stryker Corporation’s profits supported by cash flow?
Partly. Stryker Corporation kept strong full-year profitability in FY2025, but Q1 2026 margins fell as tariffs, lower manufacturing absorption, and the March 11, 2026 cyberattack hit operations. Cash generation was strong in FY2025, yet 2026-03-31 operating and free cash flow growth weakened sharply.
Stryker Corporation’s earnings quality depends on whether reported profit turns into cash. Gross margin reflects product economics, operating margin shows how well the business absorbs R&D and selling costs, and net margin captures the final result after interest and tax. FY2025 was solid, but Q1 2026 showed pressure in both margins and cash conversion.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | 6360% in Q1 2026 | 6550% in Q1 2025 | Tariffs and reduced manufacturing absorption pressured adjusted gross margins. | Product economics weakened, so each sales dollar left less gross profit. |
| Operating Margin | 2110% in Q1 2026 | 2290% in Q1 2025 | Higher operating pressure followed the gross margin decline, with costs also hit by the cyberattack. | Scale still works, but efficiency slipped versus the prior year. |
| Net Margin | Unavailable | Unavailable | Net income was $74500M at 2026-03-31, but revenue was not supplied here for a verified margin. | Final profitability cannot be measured from the supplied data alone. |
| Operating Cash Flow | Unavailable; 2026-03-31 | $504B in FY2025 | FY2025 showed strong cash generation, but 2026-03-31 operating cash flow growth was -7289%. | Reported earnings were not matching recent cash conversion as well as before. |
| Free Cash Flow | Unavailable; 2026-03-31 | Unavailable | Free cash flow growth was -7787%; capital expenditure dollars were not supplied. | Less cash appears available for reinvestment, debt service, or buybacks. |
What most affects Stryker Corporation’s cash conversion?
The biggest drag is the sharp 2026 drop in operating cash flow growth, alongside weaker margins and working-capital pressure from receivables and inventory changes.
- Main Driver: Lower absorption, tariffs, and cyberattack disruption look structural in the near term, though some pressure may be temporary.
- Evidence Gap: The supplied data does not show operating cash flow dollars or capital expenditures for 2026-03-31.
- Metric to Monitor: Watch adjusted operating margin and operating cash flow growth.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help organize the profit-and-cash story clearly. For more context, Exploring Stryker Corporation (SYK) Investor Profile: Who's Buying and Why? can help connect ownership interest with operating performance.
Moderate liquidity
Can Stryker Corporation fund operations, debt, dividends, and M&A?
Mixed. Stryker Corporation’s balance sheet has meaningful liquidity and a large asset base, but leverage and acquisition funding remain the main constraint. The chief protection is $297B of cash and short-term investments; the main concern is funding growth, dividends, and deals while keeping leverage disciplined.
Stryker Corporation’s cash position helps, but cash alone does not tell the full story. Investors should weigh working capital, asset quality, debt service, solvency, liquidity, and refinancing together, especially because acquisition spending can pressure flexibility even when near-term assets look solid.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | As of 2026-03-31, Cash And Cash Equivalents of $288B, Short Term Investments of $8700M, Cash And Short Term Investments of $297B, Net Receivables of $357B, Inventory of $542B, Total Current Assets of $1334B, and Total Current Liabilities of $632B. | Mixed | Near-term obligations look manageable, but current assets are also tied up in receivables and inventory, so liquidity depends on efficient collection and turnover. |
| Total and Net Debt | As of 2026-03-31, Long Term Debt of $1422B; Add Total Debt of $1422B and Minus Cash And Cash Equivalents of $288B support the debt picture. | Mixed | Leverage is meaningful, so debt reduces flexibility even though cash offsets part of the obligation. |
| Debt Service and Refinancing | Management’s capital allocation target is a gross debt/EBITDA ratio of approximately 21x. Market capitalization is not debt-paying capacity. May 07, 2026 quarterly dividend declared at $088 Per Share, payable July 31, 2026. | Mixed | Debt service looks supportable from scale, but refinancing and funding choices matter more if acquisition activity stays elevated. |
| Asset Quality | Total Assets of $4629B, Goodwill of $2470B, Total Non Current Liabilities of $1768B, and Other Non Current Liabilities of $345B. | Mixed | Heavy goodwill raises impairment risk, and a large intangible-heavy asset base can weaken downside protection if growth slows. |
| Liabilities and Equity | Total Current Liabilities of $632B and Total Non Current Liabilities of $1768B show a sizable liability load; equity is not supplied here. | Mixed | The liability base is large, so equity strength and cash generation need to keep absorbing investment and integration demands. |
Which balance-sheet risk matters most for Stryker Corporation?
Acquisition funding risk is the main issue, followed by leverage discipline. The AVS acquisition for approximately $835M and the Inari Medical agreement both use capital that could otherwise support debt reduction or flexibility.
- Current Exposure: $297B in cash and short-term investments versus $1422B in long term debt.
- Protection: $1334B in total current assets gives Stryker Corporation room to meet near-term needs.
- Warning Signal: Watch whether goodwill, leverage, and deal spending keep rising faster than liquidity.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For deeper academic or investment research, a DCF valuation model or company financial analysis template can help connect Stryker Corporation (SYK): History, Ownership, Mission, How It Works & Makes Money’s strategy with revenue, margins, cash flow, and valuation assumptions.
Capital Efficiency
Does Stryker Corporation reinvest cash efficiently?
Mixed. Stryker Corporation appears to fund reinvestment internally, because FY2025 Net Cash Provided By Operating Activities of $504B supports R&D, acquisitions, dividends, and working capital. The balance of strategic reinvestment and cash generation looks workable, but leverage and acquisition execution still need monitoring.
Stryker Corporation’s return profile should be read alongside leverage, asset intensity, capital expenditure, working capital, and external funding needs. The company’s cash generation helps, but capital efficiency is not the same as valuation, and strong operating cash flow does not remove integration or balance-sheet risk.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data. | No verified ROIC is provided, so operating margin strength must be judged through cash generation and reinvestment activity instead. | Investors can see that capital is being deployed, but not whether invested capital is creating operating value from a published ROIC. |
| ROE and ROA | Unavailable in the supplied data. | Without ROE or ROA, leverage and asset-efficiency effects cannot be separated cleanly. | Shareholder return quality and asset efficiency cannot be confirmed from the provided figures alone. |
| Maintenance and Growth Investment | $41300M Research And Development Expenses at 2026-03-31 and $40100M at 2025-12-31; 299% Rdexpense Growth at 2026-03-31, versus -220% at 2025-12-31. | R&D points to continued reinvestment in digital innovation, SOMA, AI, digital surgery, Mako robotic platform, Mako Shoulder scheduled for mid-2026, OptaBlate BVN clearance, Incompass Total Ankle System clearance, and Pangea Plating System launch in Europe. | Capital is being used to support product renewal and growth, not just to maintain the current business. |
| Internal Funding Capacity | FY2025 Net Cash Provided By Operating Activities of $504B; quarterly dividend of $088 per share declared May 07, 2026; Dividends Per Share Growth of 487% at 2026-03-31; Weighted Average Shares Growth of 010% and Weighted Average Shares Diluted Growth of 000% at 2026-03-31. | Operating cash appears sufficient to support reinvestment, dividends, and M&A, while share dilution looks limited in the supplied data. | Investment is mainly internally funded, which supports flexibility, but goodwill, leverage, and acquisition execution still matter. |
Are Stryker Corporation’s returns on capital sustainable?
The strongest durability factor is internal cash generation plus product and platform reinvestment. Returns could weaken if acquisition integration, leverage, or cash conversion from recent growth initiatives stops supporting the same pace of reinvestment.
- Operating Source: Cash generation and portfolio mix tied to Mako, AI, digital surgery, and new product launches.
- Funding Requirement: R&D, acquisitions like Inari Medical and AVS, and working capital needs.
- Durability Test: Slower operating cash flow, weaker cash conversion, or rising leverage would signal returns are fading.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For deeper academic or investment research, a DCF valuation model or company financial analysis template can help connect Stryker Corporation’s strategy with revenue, margins, cash flow, and valuation assumptions. You can also review Mission Statement, Vision, & Core Values (2026) of Stryker Corporation (SYK) for a fuller strategy context.
Financial resilience
How resilient is Stryker Corporation, and which warning signs matter most?
Resilience is Mixed. The main buffer is rapid restoration after the March 11, 2026 cyberattack, with operations largely back and lost Q1 revenue expected to be recovered by year-end 2026. The most important verified warning sign is margin compression from tariffs and weaker manufacturing absorption.
Stryker Corporation still has strong underlying demand and operational recovery, but it remains exposed if cybersecurity disruption, margin pressure, or legal costs hit cash generation at the same time. For company background, see Stryker Corporation (SYK): History, Ownership, Mission, How It Works & Makes Money.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | The cyberattack can disrupt operating leverage, delay earnings, and cut cash flow if sales or production slip again. | Restoration of commercial, ordering, and distribution systems was largely completed by April 01, 2026, and manufacturing returned to full operational capacity by April 30, 2026. | Watch whether Q1-to-Q4 net sales recovery falls short of Full Year 2026 Organic Net Sales Growth Guidance of 800%–950%. |
| Working-Capital or Investment Pressure | Cyber recovery, system fixes, and legal costs can absorb cash that would otherwise fund capex, R&D, and growth. | Lost Q1 revenue was expected to be recovered by year-end 2026, which supports internal funding if execution holds. | Monitor operating cash flow and any disclosed cash outflows tied to recovery or claims. |
| Interest or Refinancing Pressure | Higher financing costs would matter more if cash generation weakens and liquidity has to support recovery or litigation. | The prompt does not show debt distress, so the current issue is more operating than refinancing-related. | Watch debt levels, interest expense, and any sign that liquidity is being drawn down. |
Which financial warning signs should investors monitor at Stryker Corporation?
The top signals are adjusted operating margin, operating cash flow, and any disclosed legal cash outflows. Margin erosion is confirmed deterioration; legal exposure is still a future risk because liabilities and timing have not been quantified.
Tariff and absorption pressure on margins
Q1 2026 Adjusted Gross Margin was 6360% with Margin Decrease of 190 Basis Points, and Adjusted Operating Margin was 2110% with Margin Decrease of 180 Basis Points. The mitigation is a three-year plan for 150 basis points of margin expansion, plus supply chain diversification.
Cyber recovery fails to translate into sales recovery
The March 11, 2026 cyberattack disrupted manufacturing, order processing, and distribution and affected approximately 80,000 devices. Restoration was largely completed, but investors should still watch whether quarterly sales return to the path implied by 2026 guidance.
Legal and cybersecurity overhang
At least six employee lawsuits, shareholder investigations, and active MDL 2768 and MDL 2441 cases create uncertainty. The key question is not the lawsuit count alone but whether operating cash flow starts showing real legal or settlement-related outflows.
Balanced scorecard
How should investors score Stryker Corporation’s financial health?
Stryker Corporation scores Mixed overall. Revenue quality is the strongest factor, while latest margin pressure is the weakest; the most important condition for the investment case is whether operating performance normalizes after the Q1 2026 disruption.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | FY2025 Full Year Net Sales were $2512B with Net Sales Growth of 1116%; procedure-driven demand, installed-base revenue, and segment diversity support durability. |
| Profitability and Cash | Mixed | FY2025 Adjusted Operating Income Margin was 2630% and Net Cash Provided By Operating Activities was $504B, but Q1 2026 margins fell, showing near-term pressure. |
| Balance Sheet and Liquidity | Mixed | As of 2026-03-31, Cash And Short Term Investments were $297B versus Long Term Debt of $1422B; leverage discipline still matters around a gross debt/EBITDA ratio of approximately 21x. |
| Capital Efficiency | Mixed | Cash generation funds R&D, M&A, and dividends, but ROIC, ROE, and ROA are not supplied, and goodwill is large at $2470B, limiting clarity on returns. |
| Financial Resilience | Mixed | Operations recovered after the cyberattack, but cyber, tariff, legal, and working-capital risks remain active, so resilience looks adequate but not fully proven. |
- What Supports the Thesis: Strong full-year sales quality plus cash generation, with guidance reaffirmed for Full Year 2026 Organic Net Sales Growth Guidance of 800%–950%.
- What Challenges the Thesis: Q1 2026 gross and operating margin pressure raises the question of whether disruption truly normalizes.
- What to Monitor: adjusted operating margin, operating cash flow, gross debt/EBITDA.
For forecasts, scenarios, and valuation, the key question is whether Stryker Corporation can hold revenue momentum while restoring margins and cash conversion. Exploring Stryker Corporation (SYK) Investor Profile: Who's Buying and Why?
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
How did tariffs affect Stryker's operating margin?
Tariffs, together with reduced manufacturing absorption, pressured Q1 2026 margins Stryker reported Q1 2026 Adjusted Gross Margin of 6360% with Margin Decrease of 190 Basis Points and Adjusted Operating Margin of 2110% with Margin Decrease of 180 Basis Points
Is Stryker's cash flow still covering dividends?
The supplied data shows FY2025 Net Cash Provided By Operating Activities of $504B and a quarterly dividend declaration of $088 Per Share Dividend coverage should be tested with cash dividends paid and free cash flow dollars, which are not supplied here
How much debt does Stryker carry today?
At 2026-03-31, Stryker had Long Term Debt of $1422B and Enterprise Values data showed Add Total Debt of $1422B The same date showed Cash And Cash Equivalents of $288B No maturity schedule or average interest rate is supplied
Did the cyberattack weaken Stryker's liquidity?
The March 2026 cyberattack disrupted manufacturing, order processing, and distribution, but supplied data does not show confirmed liquidity stress Systems were largely restored by April 01, 2026, manufacturing returned to full operational capacity by April 30, 2026, and Cash And Short Term Investments were $297B at 2026-03-31
How should investors judge Stryker's reinvestment quality?
Judge reinvestment by whether R&D, M&A, and installed-base platforms support cash-backed growth without excessive leverage or dilution Evidence includes 2026-03-31 Research And Development Expenses of $41300M, the AVS acquisition for approximately $835M, and a target gross debt/EBITDA ratio of approximately 21x